Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Ambrisentan Approvals Hint At Different Commercial Approaches

Executive Summary

Four different firms have simultaneously received FDA approval for ambrisentan generics of Gilead’s Letairis. But different safety programs suggest Zydus Pharma may be taking a different commercial approach to the other three generics firms.

You may also be interested in...

US House Committee Clears Bills To Prevent Pay-For-Delay Deals, Assure Generic Access To Samples

Legislation on patent settlement agreements will not be retroactive; CREATES Act amended to give brand companies affirmative defense to litigation.

US releases guidance on REMS negotiation

Draft US guidance documents on developing a shared-system risk evaluation and mitigation strategy (REMS) and waivers for single shared-system REMS will “help generic drug makers get their products through the development and approval processes efficiently, while maintaining the safety controls”, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.

Industry peers among FDA access-denial list

Generics firms including Teva, Mylan, Sun’s Ranbaxy and Hikma’s Roxane are among almost 40 sponsors of reference drugs identified by the US Food and Drug Administration (FDA) on a list of “access inquiries” relating to difficulties experienced by generics firms in obtaining samples for development. Other companies named as sponsors of a reference listed drug (RLD) for which the FDA has received an access inquiry include originators such as AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline and Novartis.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts